Date: 2013-01-07
Type of information: Fundraising
Company: ISA Pharmaceuticals (The Netherlands)
Investors:
Amount: € 8 million
Funding type: financing round
Planned used: The proceeds will be used to fund a randomized Phase 2 clinical trial in cervical cancer with ISA Pharmaceuticals’s lead program ISA-HPV, a therapeutic vaccine for pre-malignant diseases and cancers induced by human papilloma virus (HPV).
Others: ISA Pharmaceuticals, a clinical-stage biopharmaceutical company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, has raised € 8 million in a follow-on round from its existing investor base. The proceeds will be used to fund a randomized Phase 2 clinical trial in cervical cancer with ISA Pharmaceuticals’s lead program ISA-HPV, a therapeutic vaccine for pre-malignant diseases and cancers induced by human papilloma virus (HPV).
The company has already demonstrated clinical efficacy of its HPV vaccine in a Phase II study in Vulvar Intraepithelial Neoplasia. ISA’s vaccines are based on its proprietary synthetic long peptide (SLP®) vaccine platform. The company is currently advancing existing and new programs based on its SLP® vaccine platform in a number of cancers, including cervical carcinoma, as well as its groundbreaking proprietary toll-like receptor (TLR) ligand adjuvant technology.
ISA Pharmaceuticals was founded in 2004 and has raised a total of € 20 million in private equity funding and the same amount from public grants.
Therapeutic area: Infectious diseases
